Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 1;108(2):308-320.
doi: 10.3324/haematol.2022.280801.

The clinical impact of the molecular landscape of acute myeloid leukemia

Sabine Kayser  1 , Mark J Levis  2
Affiliations
Review

The clinical impact of the molecular landscape of acute myeloid leukemia

Sabine Kayser et al. Haematologica. .

Abstract

Research into the underlying pathogenic mechanisms of acute myeloid leukemia (AML) has led to remarkable advances in our understanding of the disease. Mutations now allow us to explore the enormous diversity among cytogenetically defined subsets of AML, particularly the large subset of cytogenetically normal AML. Despite the progress in unraveling the tumor genome, only a small number of recurrent mutations have been incorporated into risk-stratification schemes and have been proven to be clinically relevant, targetable lesions. The current World Health Organization Classification of myeloid neoplasms and leukemia includes eight AML categories defined by recurrent genetic abnormalities as well as three categories defined by gene mutations. We here discuss the utility of molecular markers in AML in prognostication and treatment decision-making. New therapies based on targetable markers include IDH inhibitors (ivosidenib, enasidenib), venetoclax-based therapy, FLT3 inhibitors (midostaurin, gilteritinib, and quizartinib), gemtuzumab ozogamicin, magrolimab and menin inhibitors.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Genes recurrently mutated in acute myeloid leukemia as well as mechanism of action of targeted therapies. TCA: tricarboxylic acid cycle; IDH: isocitrate dehydrogenase; αKG: alpha-ketoglutarate; 2HG: 2-hydroxyglutarate.
See this image and copyright information in PMC

References

    1. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209-2221. - PMC - PubMed
    1. DiNardo CD, Cortes J. Mutations in AML: prognostic and therapeutic implications. Hematol Am Soc Hematol Educ Program. 2016;2016(1):348-355. - PMC - PubMed
    1. Cancer Genome Atlas Research Network Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2074. - PMC - PubMed
    1. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058-1066. - PMC - PubMed
    1. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424-2433. - PMC - PubMed

MeSH terms